Denver based company improves how Clinical Trials are managed

The majority of cancer patients in the U.S. have very limited access to the host of potentially life-saving clinical trials that are currently underway across the country. The investigational drugs they offer today in many cases will eventually become the standard of cancer treatment tomorrow. Yet more than 95% of patients who would qualify, never have the opportunity to participate in the clinical trials needed for the FDA to approve these modern anticancer drugs. The challenge with cancer clinical research is twofold. First, each trial is available at only a limited number of centers around the country. Second, patients receive care in a system of thousands of cancer centers and clinics that, if they conduct clinical trials at all, work independently from one another.
Denver based company Pharmatech is completely changing how clinical trials studies enroll cancer patients by offering a patient centered, on-demand research alternative. Pharmatech helps cancer patients identify the right trial opportunity, then activates that trial at a nearby treatment center using a Just-In-Time delivery model. The Just-In-Time research system was originally conceived by Pharmatech's founder Dr. Matthew Wiener, and its development has been supported by grants from the National Cancer Institute. According to Rob Bohacs, Pharmatech's CEO, "The process of developing patient-centric cancer trials is a breakthrough in helping both patients and pharmaceutical companies. Patient's would like to learn about clinical trials, but most can't relocate to Houston or New York just to be eligible for a trial, so why not bring the trial to the patient?"  Pharmatech's network of 300+ research sites spans most of the U.S. The Just-In-Time system allows activation of any of the clinical trials in Pharmatech's portfolio, within 10 days of confirming patient interest and fit with a specific study.